• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

    11.40 -0.01 (-0.09%)
    Streaming Delayed Price Updated: 2:50 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,691
    Open 11.38
    Bid (Size) 11.17 (100)
    Ask (Size) 11.78 (100)
    Prev. Close 11.41
    Today's Range 11.17 - 11.90
    52wk Range 0.0032 - 18.20
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    TechMediaBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
    Via Investor Brand Network
    News headline image
    Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
    From Polyrizon Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -10.6%
    -10.6%
    1 Month
    -16.8%
    -16.8%
    3 Month
    -21.9%
    -21.9%
    6 Month
    +882.8%
    +882.8%
    1 Year
    +3354.5%
    +3354.5%

    More News

    Read More
    News headline image
    Polyrizon Provides 2025 and Recent Highlights
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
    From Polyrizon Ltd.
    Via GlobeNewswire
    PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
    Via Stocktwits
    News headline image
    Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
    From Polyrizon Ltd.
    Via GlobeNewswire
    Top movers in Monday's session ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
    From Polyrizon Ltd.
    Via GlobeNewswire
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
    From Polyrizon Ltd.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Polyrizon Ltd. - Ordinary Shares publicly traded?
    Yes, Polyrizon Ltd. - Ordinary Shares is publicly traded.
    What exchange does Polyrizon Ltd. - Ordinary Shares trade on?
    Polyrizon Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Polyrizon Ltd. - Ordinary Shares?
    The ticker symbol for Polyrizon Ltd. - Ordinary Shares is PLRZ on the Nasdaq Stock Market
    What is the current price of Polyrizon Ltd. - Ordinary Shares?
    The current price of Polyrizon Ltd. - Ordinary Shares is 11.40
    When was Polyrizon Ltd. - Ordinary Shares last traded?
    The last trade of Polyrizon Ltd. - Ordinary Shares was at 04/20/26 02:50 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.